AKESO: EXCEEDED 2023 ANNUAL CAPS FORCONTINUING CONNECTED TRANSACTIONSMASTER MATERIALS AND SERVICES PROCUREMENTAGREEMENT WITH CHIA TAI TIANQING IN RELATIONTO CLINICAL TRIAL OF PENPULIMAB(PD-1 MONOCLONAL ANTIBODY, AK105)
AKESO: CONNECTED TRANSACTIONFURTHER INFORMATION IN RELATION TOACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
AKESO: CONNECTED TRANSACTION IN RELATION TOACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
AKESO, INC. - B: CONTINUING CONNECTED TRANSACTIONSWITH CHIA TAI TIANQINGIN RELATION TO PHASE III REGISTRATION TRIAL OFPENPULIMAB (PD-1 MONOCLONAL ANTIBODY, AK105) FORTHE TREATMENT OF HEPATOCELLULAR CARCINOMAMASTER MATERIALS AND SERVICES PROCUREMENT AG
AKESO, INC. - B: CONTINUING CONNECTED TRANSACTIONSFURTHER INFORMATION IN RELATION TOEXCLUSIVE SALES AGREEMENT OFPENPULIMAB MONOCLONAL ANTIBODY
AKESO, INC. - B: CONTINUING CONNECTED TRANSACTIONS EXCLUSIVE SALES AGREEMENT OF PENPULIMAB MONOCLONAL ANTIBODY
No Data